Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
Discover More about Global Responsibility
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Discover More about Global Partnering
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Menarini Blog
Follow Us
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Our Job Portal
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
2019 - 06 - 10
Menarini Ricerche at the 24th EHA congress presenting the First In Human clinical study of SEL24/MEN1703
Pomezia, Italy, June 10th , 2019 – Menarini Ricerche will present at the 24th EHA Congress 2019 in Amsterdam on the First In Human clinical trial of SEL24/MEN1703 (DIAMOND-01, NCT03008187).
During the poster session dedicated to “Acute Myeloid Leukemia - Clinical” on June 14th 2019, 17:30PM- 19:00PM, the poster “CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia” will be presented (Final Abstract Code: PF281).
This poster will report the study design of the FIH clinical trial DIAMOND-01 of SEL24/MEN1703, a molecule in-licensed from Selvita, in patients with newly diagnosed Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, and Primary Refractory Acute Myeloid Leukemia and no available therapeutic options (NCT03008187). The main objective of the study, conducted in the US, is the identification of the recommended phase 2 dose.
Menarini Ricerche is eager to present this study, which is the first trial testing a dual PIM/FLT3 inhibitor in AML. In addition, this is the first trial testing a dual PIM/FLT3 inhibitor with the potential to be a benefit for AML patients regardless of their FLT3 mutational status, and to overcome FLT3 inhibitor resistance.
The contribution of Menarini Ricerche to international conferences in Oncology, such as the EHA congress, is a key component of our commitment to developing new drugs for patients with difficult to treat cancers and poor prognosis.